Nitric oxide (NO) plays an important role in the regulation of hemostasis. This mediator is synthesized by a family of enzymes collectively known as NO synthase (NOS) (1). Several isoforms of this enzyme have been identified and can be grouped as constitutive or inducible. Endogenous generation of NO plays an important role in the regulation of both physiologic and pathologic responses. Increased production of NO is reported in several inflammatory disor-ders such as sepsis, arthritis, thrombotic thrombocytopenic purpura, and antiphospholipid syndrome (2-5). NO is generated by NOS in pathologic states and as such becomes a reactive biomolecule, when the generation of NO exceeds the antioxidant role. NO and its molecular variants are capable of damaging DNA and proteins. Nitrosylation of DNA proteins inhibits their enzymatic activity and enhances DNA damage (6). This process can also modulate effector proteins of apoptosis, especially caspases. NO can also promote angiogenesis and cancer progression (7). In addition, NO upregulates cyclo-oxygenase-2 (COX-2) and the synthesis of several other inflammatory cytokines (8, 9) . NO accounts for the cytotoxic and cytostatic effects of the immune system against infection and cancer (10).
morogenic. Various malignant tumors including renal cell, pancreas, breast, gynecologic, lung, and prostate gland overexpress NOS (11, 12) . The aims of the present study were to determine the baseline levels of this mediator and its relationship with inflammatory cytokines in cancer patients with hypercoagulable states.
MATERIALS AND METHODS

Materials
1. Unfractionated heparin was obtained from Choay Pharmaceuticals, Paris, France.
2. Reviparin (Knoll Pharma GmbH, Germany) 3. Tissue factor enzyme-linked immunosorbent assay (ELISA) kit (American Diagnostica Inc., Greenwich, CT) 4. TNF-α ELISA kit (Genzyme Diagnostics, Cambridge, MA) 5. CRP ELISA kit (American Diagnostica Inc. Greenwich, CT) 6 . ELISA reader (Dynatech MR 7000, Dynatech Laboratories, Chantilly, VA) 7. NO analyzer (Model 280i, Sievers Instruments, Boulder, CO) 8. Plasma samples from cancer patients (n= 160) were obtained from CORTES trial, ECHOS Trial, All India Institute Medical Science, New Delhi, India and University of Padova, Italy. Agematched control (n=138) plasma samples were obtained from healthy volunteers.
Methods
The standard operating procedure for nitric oxide measurement is given below.
Rinse beakers, aliquots and pipette tips at least three times with deionized water before use.
Steps to start the instrument: 1. Turn on the water bath. Make sure that the water level is at the appropriate level. 
II. Preparation of standards
1. In each of the six aliquots (prewashed with deionized water) add 900 µL of purified water for high-power liquid chromatography (HPLC).
2. Add 100 µL of 100 mM sodium nitrate solution to the first tube. Vortex to mix homogeneously. The final concentration of sodium nitrate in this tube will be 10 mM. Then perform a serial dilution taking 100 µL from the first tube and adding to the second tube. The concentration in the second tube will be 1:10 of that in the first tube (1 mM). Similarly make dilutions in all the six aliquots. The concentrations from the first to the last will be in the order of 10 mM, 1 mM, 100 µM, 10 µM, 1 µM, 100 nM. Take three more aliquots and rinse them with deionized water. To each tube add 300 µL of purified water for HPLC use. Then take 300 µL from each of the aliquots marked 100 µM, 10 µM, and 1 µM and add them to the three aliquots to obtain final concentrations of 50 µM, 5 µM, and 0.5 µM. The entire set of standards are now in the increasing order of 100 µM, 1 µM, 0.5 µM, 10 µM, 5 µM, and 10 µM. When running the standards, start from the lowest concentration to the highest concentration. At least run a three-point calibration of 10, 50, and 100 µM. Each time exactly 5 µL of the sample will be used to run the sample.
III. Preparation of vanadium chloride solution
1. Measure 0.4 g of vanadium and place in a 50-mL tube. Add 50 mL of 1N HCl. Mix well. Filter the solution by running it through filter paper. Collect the filtered vanadium chloride solution. It is a blue solution. Keep the solution refrigerated.
IV. Preparation of 1N sodium hydroxide
a. Preparation of the samples 1. Ideally the plasma samples should be centrifuged to get rid of all the cryoprecipitates. If possible, these centrifuged plasma samples should be de-proteinated by mixing one part of the sample with three parts of cold ethanol. Keep for 30 minutes. Deproteination will help prevent buildup of proteins in the purge vessel and also prevents blockade of the syringe for sample injection. Measure the sample accurately up to 15 µL for each run. However, record 5 µL on the computer. This is to compensate for the dilution of the sample with alcohol when deproteination has been confirmed. This also helps simplify the calculation of concentrations taking into account the dilution in the preparation of the sample.
b. Preparation of antifoaming agent from the concentrate Dilute 1:30 in deionized water. c. Calculation of the concentration of NO after extrapolation from the calibration curve
Obtain the concentration of NO in micromoles per liter for each sample by extrapolation from the calibration curve. Save all the data in the computer and try to obtain a hard copy for records. 
VI. Daily maintenance of the machine
After daily use cleaning of the purge vessel and the bubbler and the tubings help build up of proteins and comply with quality assurance requirements.
VII. Weekly maintenance of the machine
Weekly cleaning of the purge vessel, bubbler, and the tubings with a detergent help prevent buildup of proteins and comply with quality assurance requirements.
Procedure
The TF-ELISA, TNF-α ELISA, and CRP ELISA assays were performed according to the manufacturer recommended procedure.
RESULTS
Because of its short half-life, NO levels are usually measured by indirect methods. In these studies, a highly specific chemical method was used to quantitate the absolute level of NO in plasma samples collected from cancer patients. In healthy individuals, the NO levels were 19.8±6.2 µM. The range was between 9.1 and 34.6 µM. Cancer patients presenting with thrombotic complications, who were enrolled in different clinical trials mentioned previously, exhibited a much higher level of NO (63.1±15.9 µM), and the range was 13.7 to 98.6 µM. (Fig. 1) .
Patients with solid tumors also exhibited markedly high levels of NO along with inflammatory cytokines such as TF, TNF-α, and CRP. The baseline values of TF, TNF-α, and CRP were 96±41 pg/mL, 71±29 pg/mL, and 19±8 µg/mL, respectively. Following treatment with low-molecular-weight heparin (LMWH), the corresponding values decreased to 36±12 pg/mL, 52±15 pg/mL, and 11±5 µg/mL, respectively (Fig. 2) . The quartile analysis demonstrated that most of the cancer patients (>75%) had increased nitric oxide levels of more than 25 µM. In addition, more than 30% of patients had more than 50 µM of nitric oxide levels. However, the majority of normal subjects had less than 25 µM of nitric oxide levels (Fig. 3) . Treatment with heparin and LMWH produced a significant downregulation of NO levels (baseline, 44.25±1.98; after treatment, 27.5±2.4 µM). In a subset analysis, after treatment with heparin and LMWH, the nitric oxide levels were markedly decreased (Fig. 4) . The pathogenesis of cancer results in an upregulation of iNOS, leading to increased NO production, which is accompanied by simultaneous upregulation of inflammatory cytokines. 
DISCUSSION
The results conclusively prove that NO levels are elevated in cancer patients. The high levels of NO have been shown to be genotoxic, mutagenic, and carcinogenic by other investigators (6,7) . Furthermore, it has been shown that NO can mediate DNA damage and hindrance to DNA repair (6) . The tumor-derived NO stimulates tumor progression. Sustained release of NO may cause inflammation-mediated tissue damage and carcinogenesis (13) . Besides cancer, NO also plays an important role in the pathogenesis of other inflammatory conditions, such as septic shock. The vasopressor-resistant vasodilatation in sepsis is attributed to the sustained increased NO levels. Downregulation of NO levels by heparins, which reduce the inflammation, is critical in the management of sepsis (2) .
Anticoagulant drugs, such as unfractionated heparin and LMWHs, are known to have anti-inflammatory effects due to release of tissue factor pathway inhibitor (TFPI). The results from this study confirm this finding. Cancer is associated with a hypercoagulable state and inflammation. The treatment of hypercoagulation and inflammation is important in the management of cancer. Through their anticoagulant effects, heparin and LMWHs can prevent the hypercoagulable state and resulting thromboembolic complications. Furthermore, the release of TFPI due to heparins can have an anti-inflammatory effect (14) . These results show that heparins given to cancer patients can decrease the level of NO. However, the mechanism of action of heparins to decrease NO is not fully understood. Perhaps the release of TFPI, which has an anti-inflammatory effect, may alter the levels of NO. Such a decrease in the sustained levels of NO is important in the management of hypotension and inflammation in sepsis and also in cancer patients. There have been several unsuccessful attempts to inhibit NO levels in patients with septic shock to obtain vasopressor-responsive vasodilatation (15) . Besides NO, there are several inflammatory markers such as tissue factor, TNF-α and CRP, levels of which are elevated in cancer. Treatment of these cancer patients with heparins has shown a marked reduction in the levels of these markers. The hypercoagulable state in cancer may be attributed to the increased levels of TF. TFPI is released due to the production of TF, but the heparin-mediated release of TFPI is enormous (16) . TFPI is a protease inhibitor with three Kunitz type domains. It inhibits the generation of activated fac-tor X (FXa) by FVIIa/TF complex. At first, the second Kunitz type domain of TFPI combines with FXa to form TFPI/FXa complex. The TFPI/FXa complex then combines with FVIIa/TF complex to form a TFPI:FXa:FVIIa:TF quaternary inhibitory complex (17) . TFPI expression could also be mediated by the release of cytokines and growth factor through the signaling pathways involving protein kinase C, epidermal growth factor-1 (EGF-1), NFκ-B/REL, and MEK/ERK-1/2 (18, 19) . The increased levels of cytokines in cancer can trigger the TF expression, resulting in a hypercoagulable state and thrombosis. This significant increase of TF is decreased by heparins, which cause an increase in TFPI. The TF forms a complex with factor VIIa (FVIIa) and blood coagulation is initiated. TFPI, multivalant inhibitor regulates coagulation by factor Xa-dependent inhibition of the TF/FVIIa complex (20) . The function of the third Kunitz type domain of TFPI is not fully understood (21) . The activation of factor VII through interaction with TF and formation of TF/FVIIa complex is of prime importance in the initiation of thrombin generation and fibrin deposition, which are angiogenic. Thrombin induces angiogenesis without fibrin deposition or platelet secretion (22) . Furthermore, thrombin receptor activation on endothelial cells induces transcription of VEGF-R1 and VEGFR-2 for maximum stimulation of angiogenesis (23) . The cytoplasmic tail of the TF/FVIIa complex is responsible for the increased VEGF-A expression seen in cancer patients (24, 25) . The control of increased levels of TF through administration of heparins will not only benefit in control of the hypercoagulable state; inhibition of the TF/FVIIa complex by TFPI can also control angiogenesis.
Tissue factor also binds plasminogen at a different site than FVIIa. This inhibits fibrinolysis. When endothelial cells become angiogenic, they can express urokinase plasminogen activator, MT1-MMP, and tissue factor, which may provide plasminogen for the generation of plasmin and angiostatin (24, 25) .
The excess thrombin generated is enzymatically neutralized by ATIII and results in the generation of anti-angiogenic fragment of ATIII (aaATIII). Neutralization of thrombin by heparins and production of aaATIII causes inhibition of angiogenesis besides limiting coagulation (26) . The increased levels of inducible NO in cancer patients and the increased levels of thrombin that are known to cause angiogenesis can be controlled by administration of heparins. Our findings on the increased level of NO in patients with cancer are consistent with previously reported data. The degree of increase may be useful in the risk stratification of these patients. Our results also support the view that therapeutic interventions especially with anticoagulant drugs such as the LMWHs contribute to the downregulation of NO in these patients thereby mediating anti-inflammatory effects in cancer patients. Increased NO levels result in an upregulation of iNOS and therefore targeted therapy to inhibit the iNOS or modulation of L-arginine pathways may be a useful adjunctive approach in the treatment of cancer patients. Additional well-controlled studies are needed to validate these observations.
CONCLUSIONS
The upregulation of NO in cancer patients strongly suggests the multifactorial pathogenesis associated with different malignancies. Modulation of L-arginine/NO system might be helpful as an adjunctive treatment strategy to improve current treatment modalities. Downregulation of NO levels by heparin is critical in the management of cancer and inflammatory disorders. Heparins should therefore be included as adjunctive therapy.
CLINICAL IMPLICATIONS
1. Elevated levels of NO in cancer patients are highly suggestive of inflammatory responses. These NO measurements may be helpful in the prognosis of cancer patients.
2. Anti-inflammatory drugs and iNOS inhibitors may be useful in the adjunctive treatment of patients with cancer.
3. Pharmacologic intervention with different anti-cancer drugs may also downregulate iNOS, which can be measured by quantitating NO levels in these patients. 4 . The observed therapeutic effects of LMWHs in cancer may be related to the anti-inflammatory and anti-angiogenic effects and downregulation of NO and NO-mediated pathophysiologic processes.
5. The role of other newly developed anticoagulant drugs such as antithrombin, anti-Xa drugs and the synthetic heparinomimetics in the regulation of NO pathways in cancer remain to be elucidated.
